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Abstract
Background: Low Molecular Weight Heparins (LMWH) are at least as effective antithrombotic drugs as Unfractionated
Heparin (UFH). However, it is still unclear whether the safety profiles of LMWH and UFH differ. We performed a systematic
review to compare the bleeding risk of fixed dose subcutaneous LMWH and adjusted dose UFH for treatment of venous
thromboembolism (VTE) or acute coronary syndromes (ACS). Major bleeding was the primary end point.
Methods: Electronic databases (MEDLINE, EMBASE, and the Cochrane Library) were searched up to May 2010 with no
language restrictions. Randomized controlled trials in which subcutaneous LMWH were compared to intravenous UFH for
the treatment of acute thrombotic events were selected. Two reviewers independently screened studies and extracted data
on study design, study quality, incidence of major bleeding, patients’ characteristics, type, dose and number of daily
administrations of LMWH, co-treatments, study end points and efficacy outcome. Pooled odds ratios (OR) and 95%
confidence intervals (CI) were calculated using the random effects model.
Results: Twenty-seven studies were included. A total of 14,002 patients received UFH and 14,635 patients LMWH. Overall,
no difference in major bleeding was observed between LMWH patients and UFH (OR= 0.79, 95% CI 0.60–1.04). In patients
with VTE LMWH appeared safer than UFH, (OR = 0.68, 95% CI 0.47–1.00).
Conclusion: The results of our systematic review suggest that the use of LMWH in the treatment of VTE might be associated
with a reduction in major bleeding compared with UFH. The choice of which heparin to use to minimize bleeding risk must
be based on the single patient, taking into account the bleeding profile of different heparins in different settings.
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Introduction
In daily clinical practice, low molecular weight heparins
(LMWH) and unfractionated heparin (UFH) are the most
commonly prescribed anticoagulant drugs for the treatment of
acute thrombotic conditions, such as venous thromboembolism
(VTE) and acute coronary syndromes (ACS).
LMWH have some advantages over UFH, including higher
bioavailability and a more predictable anticoagulant effect. These
properties allow the use of LMWH at weight-adjusted doses in
most patients, without the need for laboratory monitoring. On the
other hand, although treatment with UFH needs laboratory
monitoring with Activated Partial Thromboplastin Time (aPTT),
because its anticoagulant effect is unpredictable, it has the
advantage that bleeding complications can be more easily
managed, because UFH has a shorter half-life than LMWH,
and can be effectively antagonized by protamine [1].
The antithrombotic efficacy of LMWH and UFH in the
treatment of VTE and ACS has been evaluated in many
randomized clinical trials and analyzed in several meta-analyses.
Treatment of VTE with LMWHs is associated with similar or
lower rates of recurrences and death as compared to treatment
with UFH [2;3]. However, there is no evidence that LMWH are
more effective than UFH in patients with ACS [4].
Minimizing the bleeding risk in patients treated with anticoag-
ulants is of utmost clinical relevance, considering that major
bleeding, anemia and blood transfusion are powerful and
independent predictors of morbidity and mortality in patients
with VTE or ACS on treatment with antithrombotic drugs [5–7].
To date, the systematic reviews comparing LMWH and UFH,
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focused on drug efficacy as primary end point and considered the
incidence of bleeding a secondary end point. This choice could
have affected the selection of studies to be included in the analysis,
since some studies reporting haemorrhagic events could have been
excluded due to the absence of the primary end point considered
as inclusion criteria in those meta-analysis.
It has not been established yet whether the incidence of bleeding
complications differs between LMWH and UFH.
Aim of our study was to perform a systematic review of
randomized clinical trials to compare the incidence of major
bleeding associated with the use of subcutaneous LMWH and
intravenous UFH for treatment of acute VTE or ACS.
Materials and Methods
Data Sources and Searches
We attempted to identify all relevant published randomized
controlled trials (RCT) that compared fixed-dose subcutaneous
LMWH with adjusted-dose intravenous UFH in the initial
treatment of thrombotic episodes. We searched MEDLINE,
EMBASE and the Cochrane Central Register of Controlled
Trials, using the search terms ‘‘randomized controlled trials’’ and
‘‘heparin’’ in combination with generic and trade names of
individual preparations of LMWH. The search was completed in
May 2010. We manually searched the references of retrieved
publications to look for additional studies. No language restrictions
were applied. Two investigators (EC, AMR) independently
evaluated the studies for inclusion, and disagreements were
resolved by discussion.
Study Selection
In order to be included in this systematic review, published
studies had to meet the following criteria: 1) study design:
randomized controlled trial; 2) intervention: comparison of
subcutaneous weight-adjusted, fixed-dose LMWH with adjusted
doses (based on APTT values) intravenous UFH, for the initial
treatment of acute thrombotic episodes; 3) availability of outcome
data on the incidence of major bleeding. We accepted the
definitions of major bleeding that were chosen in each individual
trial. Dose-finding studies were excluded. Studies with no events in
both LMWH and UFH arms were included in the descriptive
analysis, but excluded from the meta-analysis, because calculation
of the odds ratio (OR) was not feasible.
Pre-defined subgroup analyses were performed on the basis of
the type of disease that was treated (VTE vs ACS), the doses of
LMWH that were administered, the number of daily administra-
tions of LMWH (one or two) and the type of LMWH used.
Quality Assessment
In order to evaluate the quality of the included studies, we used
the study-quality criteria of Jadad, which take into account proper
randomization, allocation of patients and blinding [8].
Data Extraction
Two investigators (EC, AMR) independently extracted the data
on study design, study quality, incidence of major bleeding,
patients’ characteristics, type, dose and number of daily admin-
istrations of LMWH, co-treatments, study end points and efficacy
outcome. The data extracted for each trial were confirmed by
consensus between the reviewers.
Data Analysis
For each primary study that was included in the meta-analysis, a
two-by-two table was constructed and the OR, with their 95%
confidence intervals (CI), were calculated to estimate the risk of
major bleeding in patients treated with LMWH compared to
patients treated with UFH.
Pooled OR and 95% CI were calculated using the random
effects model [9]. The homogeneity of the estimates of OR among
studies was evaluated using the chi-square statistic test. Given the
known difference of clinical settings of primary studies included in
our meta-analysis (clinical heterogeneity), random effects analysis
was performed for all studies, irrespective of the statistical
significance of the heterogeneity chi-square test.
All analyses were performed using STATA 11.0 software [10].
Results
Study Selection
Figure 1 shows the process of study selection. We identified
6513 articles (1498 from Medline, 3205 from Embase, 1810 from
the Cochrane Library). Of these, 1515 studies were duplicates,
which were therefore eliminated, leaving 4998 articles for
consideration. After the exclusion of irrelevant studies, which
were identified by reviewing the titles and abstracts of all retrieved
articles, 112 publications remained for analysis. We could not
obtain the full publication of 19 studies after searching in the
British Library and writing to the authors. Fifty-four of the
remaining 93 articles were subsequently excluded, based on a
more detailed evaluation of the full publications (Fig. 1). No
additional studies were identified by reviewing the references from
the original studies and other meta-analyses. One study, which
operated a double randomization was considered as two data sets
[11]. Thus, 37 studies were included in the descriptive analysis
[11–47]. In 10 of them, no bleeding events were observed in any
treatment group: therefore, 27 studies were included in the meta-
analysis [12–15;17–38;47].
Table 1 describes the characteristics of the included studies.
Thirty-four studies were published in English, one in French and
two in Spanish, in journals of Internal Medicine, Cardiology,
Hematology, or, less frequently, Angiology and Pneumology. The
years of publication ranged between 1989 and 2006. Twenty-six
studies enrolled patients with VTE, 11 studies enrolled patients
with ACS (STEMI, NSTEMI, unstable angina). Nine different
types of LMWH were used: the most commonly used one was
enoxaparin. In all studies, the dose of intravenous UFH was
titrated to maintain the APTT ratio between 1.5 and 2.5. The
daily doses of subcutaneous LMWH ranged between 90 and 300
anti-Xa U/kg (mean 195 U/kg), in one or two daily administra-
tions (9 and 28 studies respectively); one study allowed both the
once daily and the twice daily administration [30]. Treatments
lasted between 2 and 28 days (mean, 8 days). Concomitant
medications for patients with ACS included Aspirin, Aspirin plus
a thienopiridine, Aspirin plus a GPIIb-IIIa inhibitor, or Aspirin
plus a thrombolytic agent. Most studies used the TIMI criteria to
define major bleeding [48].
A total of 28,637 patients had been enrolled in the studies,
14,635 of whom were treated with LMWH and 14,002 with UFH.
The mean number of patients enrolled in each trial was 754 (range
20–9,978 ), their mean age was 62 y (range 49–73), and 63%
(range 31–83%) were men.
The aim of the majority of the studies was to evaluate combined
end-points; less frequently, a single clinical end-point or an
instrumental measure were evaluated. Major bleeding ranged
from 0 to 12.5%, (mean, 4.4%) in patients treated with LMWH
and from 0 to 11.5% (mean, 4.4%) in patients treated with UFH.
The mean incidence of bleeding events were lower in VTE (1.1%
with LMWH and 1.9% with UFH), compared to ACS (5.8% with
Heparins and Bleeding: A Systematic Review
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e44553
Figure 1. Study selection progression.
doi:10.1371/journal.pone.0044553.g001
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dosage of LMWH Cotreatments
Riess H et al. 2003 VTE LMWH 627 6 (1.0) 61 Certoparin, 8000 IU, bid None
UFH 593 7 (1.3)
Decousus et al. 1998 VTE LMWH 195 7 (3.6) 72 Enoxaparin, 100 IU/Kg, bid None
UFH 205 8 (3.9)
Columbus investigators 1997 VTE LMWH 510 10 (2.0) 60 Reviparin, 3500–6300 IU, bid None
UFH 511 8 (1.6)
Zhang Wang et al. 2006 ACS LMWH 96 1 (1.0) 66 Parnaparin, 4250 IU, bid ASA, UK
UFH 90 3 (3.1)
Hull et al. 1992 VTE LMWH 213 1 (0.5) No data Tinzaparin, 175 IU/Kg, qd None
UFH 219 11 (5.0)
Collaborative European
Multicentre Study 1991
VTE LMWH 85 2 (2.4) No data Nadroparin, 12500–17500 IU, bid None
UFH 81 4 (4.9)
Campos et a. 2002 ACS LMWH 107 1 (0.9) 60 Enoxaparin, 80 IU/Kg, bid ASA
UFH 96 9 (9.4)
Goldhaber et al. 1998 VTE LMWH 41 1 (2.4) 54 Ardeparin, 130 /Kg, bid None
UFH 39 1 (2.6)
Simonneau et al. 1997 VTE LMWH 304 3 (1.0) 67 Tinzaparin, 175 IU/Kg, qd None
UFH 308 5 (1.6)
PRIME CARE Study
Investigators Group 2005
ACS LMWH 451 2 (0.4) 57 Parnaparin, 6400 IU, qd ASA
UFH 446 2 (0.4)
Goodman et al. 2003 ACS LMWH 380 8 (2.1) 64 Enoxaparin, 100 IU/Kg, bid ASA, EPF
UFH 366 20 (5.5)
Kakkar et al. 2003 VTE LMWH 126 0 (0) No data Bemiparin, 115 IU/Kg, qd None
UFH 126 1 (1.0)
Prandoni et al. 1992 VTE LMWH 85 1 (1.2) No data Nadroparin, 12500–17500 IU, bid None
UFH 85 3 (3.5)
Levine et al. 1996 VTE LMWH 247 5 (2.0) 58 Enoxaparin, 100 IU/Kg, bid None
UFH 253 3 (1.2)
Gurfinkel et al. 1995 ACS LMWH 68 0 (0) 63 Nadroparin, 214 IU/Kg, bid ASA
UFH 70 2 (2.9)
Harenberg et al. 2000 VTE LMWH 265 4 (1.5) 62 Certoparin, 8000 IU, bid None
UFH 273 11 (4.0)
Cohen et al. 2002 ACS LMWH 315 4 (1.3) 64 Enoxaparin, 100 IU/Kg, bid ASA, TFB
UFH 210 3 (1.4)
Blazing et al. 2004 ACS LMWH 2026 18 (0.9) 61 Enoxaparin, 100 IU/Kg, bid ASA, TFB
UFH 1961 8 (0.4)
Breddin et al. 2001 VTE LMWH 762 2 (0.3) 59 Reviparin, 7000–12600 IU, qd or bid None
UFH 375 2 (0.6)
Perez de Llano et al. 2003 VTE LMWH 29 1 (3.4) No data Enoxaparin, 100 IU/Kg, bid None
UFH 21 0 (0)
Fiessinger et al. 1996 VTE LMWH 120 0 (0) 61 Dalteparin, subcutaneous bolus
5000 IU, then 200 IU/kg qd
None
UFH 133 2 (1.5)
Harenberg et al. 1990 VTE LMWH 24 3 (12.5) 61 Certoparin, 150 IU/Kg, bid None
UFH 26 3 (11.5)
Luomanmaki et al. 1996 VTE LMWH 117 0 (0) 59 Dalteparin, subcutaneous bolus
5000 IU, then 200 IU/kg qd
None
UFH 131 1 (0.8)
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LMWH and 5.4% with UFH). Considering the efficacy end-
points, 15 studies showed that LMWH were superior to UFH
[12;15;17–19;21–23;26;27;29;30;36;40;42], 1 study showed that
UFH was superior to LMWH [46], while the remaining 21
showed that there was no statistically significant difference
between the two treatments [11;13;14;16;20;24;25;28;31–35;37–
39;41;43–45;47].
Assessment of Study Quality
Based on the study-quality criteria of Jadad [8], 3 studies scored
1 point, 17 scored 2 points, 14 scored 3 points, 1 scored 4 points
and 2 scored 5 points. Lack of blindness was the most common
flaw in the studies with a low Jadad score.
Data Synthesis
Pooled estimates of ORs for major bleeding showed a non-
statistically significant trend in favor of LMWH compared to UFH
(OR=0.79, 95% CI: 0.60–1.04, p = 0.091; n= 27 primary studies)
(Figure 2).
When the analysis was limited to trials that enrolled patients
with VTE, pooled estimates of OR was in favor of LMWH
(OR=0.68, 95% CI: 0.47–1.00, p = 0.05) (figure 3).
Study Characteristics
In contrast, when the analysis was limited to trials that enrolled
patients with ACS, no statistically significant differences between
LMWH and UFH were found (OR=0.87, 95% CI: 0.59–1.29;









dosage of LMWH Cotreatments
Koopman et al. 1996 VTE LMWH 202 1 (0.5) 60 Nadroparin, 8200–18400 IU, bid None
UFH 198 2 (1.0)
Cohen et al. 1997 ACS LMWH 1607 102 (6.3) 63 Enoxaparin, 100 IU/Kg, bid ASA
UFH 1564 107 (6.8)
SYNERGY Trial Investigators
2004
ACS LMWH 4993 453 (9.1) 68 Enoxaparin, 100 IU/Kg, bid ASA clopidogrel/
antiIIb/IIIa
UFH 4985 379 (7.6)
Kirchmaier et al. 1998 VTE LMWH 128 1 (0.8) 61 Certoparin, 8000 IU, bid None
UFH 131 4 (3.1)
Belcaro et al. 1999 VTE LMWH 98 0 (0) 53 Nadroparin, 100 IU/Kg, bid None
UFH 97 0 (0)
Malhotra et al. 2001 ACS LMWH 51 0 (0) 60 Enoxaparin, 100 IU/Kg, bid ASA
UFH 42 0 (0)
Moreno Palomares et al. 2001VTE LMWH 17 0 (0) 67 Dalteparin, 200 IU/Kg qd None
UFH 15 0 (0)
Simonneau et al. 1993 VTE LMWH 67 0 (0) 62 Enoxaparin, 100 IU/Kg, bid None
UFH 67 0 (0)
Meyer et al. 1995 VTE LMWH 29 0 (0) 61 Dalteparin, 120 IU/kg, bid None
UFH 31 0 (0)
Findik et al. 2002 VTE LMWH 29 0 (0) 50 Enoxaparin, 100 IU/Kg bid None
UFH 30 0 (0)
Lindmarker et al. 1994 VTE LMWH 101 0 (0) 61 Dalteparin, 200 IU/Kg, qd None
UFH 103 0 (0)
Stricker et al. 1999 VTE LMWH 9 0 (0) 66 Nadroparin, 185 IU/Kg, qd None
UFH 11 0 (0
Kim et al. (a) 2005 ACS LMWH 40 0 (0) 63 Dalteparin, 120 IU/Kg, bid ASA, Clopidogrel
UFH 40 0 (0)
Kim et al. (b) 2005 ACS LMWH 40 0 (0) 59 Dalteparin, 120 IU/Kg, bid ASA, Clopidogrel,
TFB
UFH 40 0 (0)
Aiach et al. 1989 VTE LMWH 31 0 (0) 62 Dalteparin, 100 IU/Kg bid, then in
function of antifactor Xa, bid
None
UFH 30 0 (0)
n: numbers; LMWH: low molecular weight heparin; UFH: unfractioned heparin; VTE: venous thromboembolism; ACS: acute coronary syndrome; qd: once daily; bid:
twice daily; tid: three times a day; UK: urochinasi; TFB: tirofiban; EPF: eptifibatide; antiIIb/IIIa: GPIIb/IIIa inhibitors; ASA: acetylsalicylic acid.
doi:10.1371/journal.pone.0044553.t001
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Once daily LMWH was significantly safer than UFH,
(OR=0.39, 95% CI: 0.16–0.95, p= 0.039), while, for twice daily
LMWH, no statistical difference was observed compared to UFH
(OR=0.86, 95% CI: 0.65–1.14, p= 0.296) (figure S1). When the
analysis was limited to the subgroup of VTE trials, once daily
LMWH was significantly safer than UFH (OR=0.31, 95% CI:
0.12–0.84), while no significant differences were found when
considering the other subgroups (VTE twice, ACS once and ACS
twice) (figure S2).
The exclusion of studies in which LMWH was under-dosed (less
than 75% of the recommended daily dose) or overdosed (more
than 125% of the recommended dose) did not substantially change
the results (OR=0.79, CI 95% 0.58–1.06, p = 0.121) (figure S3).
No statistically significant differences among different LMWH
were observed (figure S4).
The results did not change, after Exclusion of the low quality
studies (Jadad score ,3) from the analysis (OR=0.88, 95% CI:
0.67–1.15, p = 0.342) (figure S5).
Based on our a priori defined protocol, we excluded dose-
finding studies [49–52], which had been included in other
revisions. In particular, in the VTE setting, the study by Merli
et al., which used two different LMWH doses, compared to a
single UFH group, was excluded despite the large number of
patients enrolled. For the sake of completeness, we repeated our
analysis including the dose-finding trials and the results did not
change (figure S6).
Discussion
Our systematic review shows a trend toward a non-statistically
significant lower incidence of major bleeding with LMWH
compared to UFH (OR 0.79), in the treatment of acute
thrombotic events, such as VTE and ACS. When we analyzed
separately the RCT that enrolled VTE patients and those
enrolling ACS patients, the reduction in the bleeding risk
associated with LMWH (OR=0.68, p= 0.05) reached statistical
significance for VTE. Some reasons might explain the absence of
significant difference in bleeding between LMWH and UFH in
ACS patients: i) many ACS patients underwent invasive proce-
dures (coronary angiography and PCI), ii) ACS patients were often
in co-treatment with antiplatelet agents; iii) LMWH patients are
likely to be more often in the therapeutic range compared to dose
adjusted UFH.
Somewhat unexpectedly, the incidence of bleeding complica-
tions was significantly lower with once daily administrations of
LMWH, compared to twice daily administrations, the total daily
Figure 2. Pooled estimates of OR for major bleedings of LMWH versus UFH in all patients.
doi:10.1371/journal.pone.0044553.g002
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doses being similar in the two treatment regimens (figure S1).
Although we have not a clear explanation of these results, it could
be speculated that bleeding correlates better with the trough drug
concentrations (lower in once a day than in twice a day
administrations) than with peak concentrations (higher in daily
administration).
Anyway, our findings raise the possibility that dosing regimens
can be important determinants for bleeding complications.
Further studies should clarify this topic.
The use of LMWH and UFH for treatment of VTE and ACS
has been evaluated in previous systematic reviews and meta-
analyses, which were focused on their antithrombotic efficacy as
primary end-point. However, in consideration of the negative
impact on mortality and adverse cardiovascular events associated
with major bleeding [5–7], it is also important to establish which
treatment is safer, in terms of incidence of bleeding complications.
As far as treatment of VTE is concerned, only the meta-analysis
of Lim et al on LMWH-associated bleeding is available to date
[53], which demonstrated a higher incidence of bleeding
complications in patients with renal failure, without comparing
LMWH with UFH. Information on the difference in bleeding
complications between LMWH and UH is retrievable from two
other meta-analyses, which were mainly focused on evaluating the
differences in efficacy between the two treatments [2;3]. Quinlan
et at. reported a non-statistically significant trend toward lower
frequency of major bleeding associated with LMWH, compared to
UFH (1.4% vs 2.3%, OR 0.67, 95% CI 0.36–1.27), in patients
with non-massive pulmonary embolism [2]. In the Systematic
Review of the Cochrane Collaboration on VTE [3], LMWH were
shown to be significantly safer than UFH (incidence of major
bleeding, 1% vs 2.1%, OR 0.57; 95% CI 0.39–0.83). While, at a
first glance, our review seems to be very similar to the Cochrane
review, we think that they are basically different. The recently
published Cochrane meta-analysis focused on the comparison
between LMWH and unfractionated heparin (UFH in terms of
their efficacy for the initial treatment of venous thromboembolism
(VTE). In our manuscript we have chosen the safety of these drugs
for the initial treatment of acute thrombotic events as primary end
point. As a consequence, in our review all the studies reporting
haemorrhagic events, irrespective of the efficacy endpoint that was
reported, have been included. As a consequence, compared to the
Cochrane meta-analysis, 9 additional studies were included in our
descriptive analysis [19;23;30;31;33;41;43;46;47], 6 of which were
also included in our meta-analysis [31;33;41;43;46;47]. These
additional studies account for 1344 more VTE patients included in
our analysis.
As far as ACS treatment is concerned, three meta-analysis have
recently been published, which gave contrasting results. Magee et
al [54], consistently with our data, showed a similar rate of major
bleeding in LMWH and UFH-treated patients with ACS (RR=1),
despite the fact that only one of the 7 studies included by Magee
met our inclusion criteria. In contrast, Murphy et al [55], who
analyzed studies comparing enoxaparin and UFH only, found an
excess of major bleeding in the enoxaparin group (OR 1.25,
Figure 3. Pooled estimates of OR for major bleedings of LMWH versus UFH in VTE patients.
doi:10.1371/journal.pone.0044553.g003
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p= 0.019). We have no explanation for the contrasting results of
the analysis by Murphy et al, compared to those of the study by
Magee et al and of our systematic review. The fact that Murphy et
al [55] focused on studies that used enoxaparin only does not
apparently account for the differences in results, because, when we
restricted our analysis to studies that used enoxaparin only, we
found no statistically significant differences in the incidence of
major bleeding between the enoxaparin group and the UFH
group (figure S4). The inclusion of studies that administered
enoxaparin either intravenously or subcutaneously in the meta-
analysis by Murphy et al might account for the different results
obtained in our meta-analysis, which included those studies that
administered LMWHs subcutaneously only. This concept seem to
be strengthened by the most recent meta-analysis by Silvain et al
[56], that enrolled RCT’s and registers studies and included only
patients treated with enoxeparin during percutaneous coronary
interventions. While they find an important reduction in major
bleeding in patients treated with intravenous Enoxeparin, the risk
of bleeding using Enoxeparin by the subcutaneous route was the
same as UFH.
The results of our study may have important clinical
implications. Patients at high risk for thrombotic events are often
also at high risk for bleeding [57;58]. Iron deficiency anemia and/
or hemorrhagic diathesis are common co-morbidities. In this
context, the choice of the best anticoagulant treatment should be
done taking into account the risk of adverse events more than the
therapeutic efficacy. As a matter of fact, minimizing the bleeding
risk in patients treated with anticoagulants is of utmost clinical
relevance, considering that major bleeding, anemia and blood
transfusion are powerful and independent predictors of morbidity
and mortality in patients with VTE or ACS on treatment with
antithrombotic drugs [5–7]. LMWH has the advantages of
subcutaneous administration, more predictable anticoagulant
response, lack of the need for laboratory monitoring and probably
less risk of major bleeding in the VTE. On the other hand the lack
of complete antagonization by antidotes and the long acting profile
can be a disadvantage in active bleeding patients. UFH is less easy
to handle, but the presence of an antidote and its brief half life
could be arguments to consider in choosing the type of heparin to
use in high bleeding risk patients who need anticoagulation. The
choice must be based on the single patient and on the clinical and
practical context, taking into account the bleeding profile of
different heparins in different settings.
Limitations
The major limitation of our systematic review is the clinical
heterogeneity between studies, especially considering all the trials
together. Sources of clinical heterogeneity are several.
The primary outcome of our systematic review, major bleeding,
was the secondary end-point of the original RCT that we
considered in our analysis. As we included all the RCT that
compared subcutaneous LMWH with UFH, we considered
different clinical scenarios and consequently different study
designs, in which heparins were used at different doses and with
different co-therapies. However, our results should not be affected
by these factors, since we considered randomized studies only.
Moreover, trying to take into account clinical heterogeneity, we
used a random effect model for the analysis, which is known to be
more conservative.
Figure 4. Pooled estimates of OR for major bleedings of LMWH versus UFH in ACS patients.
doi:10.1371/journal.pone.0044553.g004
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We chose the criteria that had been used in the original studies
as criteria for major bleeding and this could account for some of
the heterogeneity present in our results. However, most studies
considered the following major bleeding events, which are
undoubtedly clinically relevant: i) the presence of intracranial or
retroperitoneal haemorrhage, ii) haemorrhage that led directly to
death, necessitated transfusion or led to the interruption of
antithrombotic treatment, iii) a $2 g/dl decrease in the haemo-
globin concentration.
Finally, in the arterial setting clinical and statistical heteroge-
neity does not allow to derive definitive conclusions; vice versa, in
venous setting the sources of clinical heterogeneity are lower as
confirmed by the absence of statistical heterogeneity.
In conclusion, the results of our systematic review suggest that
LMWH might have a better safety profile than UFH in the
treatment of VTE, while no differences between the two
treatments was detected in ACS. The choice of which heparin
to use to minimize bleeding risk must be based on the single
patient and on the clinical and practical context, taking into
account the bleeding profile of different heparins in different
settings.
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